A244460 Stock Overview
OLIPASS Corporation, together with its subsidiaries, focuses on developing therapeutic products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OLIPASS Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩492.00 |
| 52 Week High | ₩4,245.00 |
| 52 Week Low | ₩421.00 |
| Beta | 0.60 |
| 1 Month Change | -33.60% |
| 3 Month Change | -10.38% |
| 1 Year Change | -88.04% |
| 3 Year Change | -94.11% |
| 5 Year Change | n/a |
| Change since IPO | -97.02% |
Recent News & Updates
Shareholder Returns
| A244460 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 2.5% | 4.1% | 0.5% |
| 1Y | -88.0% | 6.6% | 4.7% |
Return vs Industry: A244460 underperformed the KR Biotechs industry which returned 6.6% over the past year.
Return vs Market: A244460 underperformed the KR Market which returned 4.7% over the past year.
Price Volatility
| A244460 volatility | |
|---|---|
| A244460 Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A244460's share price has been volatile over the past 3 months.
Volatility Over Time: A244460's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 78 | Shin Chung | www.olipass.com |
OLIPASS Corporation, together with its subsidiaries, focuses on developing therapeutic products in South Korea. The company develops its products using its novel PNA based technologies. Its products pipeline includes, SCN9A for pain; PCSK9 for hyper cholesterolemia; VEGF; HIF-1a; Dystrophin; and PTP1B products.
OLIPASS Corporation Fundamentals Summary
| A244460 fundamental statistics | |
|---|---|
| Market cap | ₩17.13b |
| Earnings (TTM) | -₩16.72b |
| Revenue (TTM) | ₩5.25b |
3.3x
P/S Ratio-1.0x
P/E RatioIs A244460 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A244460 income statement (TTM) | |
|---|---|
| Revenue | ₩5.25b |
| Cost of Revenue | ₩655.19m |
| Gross Profit | ₩4.60b |
| Other Expenses | ₩21.31b |
| Earnings | -₩16.72b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -480.08 |
| Gross Margin | 87.52% |
| Net Profit Margin | -318.36% |
| Debt/Equity Ratio | 193.0% |
How did A244460 perform over the long term?
See historical performance and comparison